The challenges with antibody-based targeting of VEGF
Antibody-based targeting of vascular endothelial growth factor (VEGF) is a highly successful and widely-used clinical treatment for angiogenesis-related diseases. Currently, bevacizumab (Avastin; Genentech) and ranibizumab (Lucentis; Genentech/Roche) are the leading antibody drugs for targeting VEGF...